The pharmacist in Dartmouth noticed it first. A young man, mid-twenties, came in three times in one week asking about refills for a benzodiazepine he’d never been prescribed. His hands shook. His eyes darted. When she gently pressed him on where he’d gotten the medication, he left without another word. Two days later, paramedics brought someone from the same neighbourhood to the emergency room after a suspected overdose. The pill they found in his pocket looked legitimate at first glance, down to the manufacturer’s stamp and scoring line. But it wasn’t.
Across Nova Scotia, a synthetic version of a widely prescribed anti-anxiety medication has begun circulating on the street, and health officials are raising alarms. Unlike counterfeit pills that mimic opioids or stimulants, this new substance replicates the chemical structure of benzodiazepines but with dangerous modifications that make it far more potent and unpredictable. Police and public health teams are working to identify its exact composition, but early reports suggest it may be up to ten times stronger than the pharmaceutical version, with a high risk of dependence after just a few uses.
The drug surfaced in Halifax in early February, then spread to smaller communities along the South Shore and Cape Breton. Emergency departments have reported a spike in admissions involving seizures, respiratory depression, and extreme sedation. Some patients arrive unconscious. Others become combative or confused, a pattern health workers say is consistent with benzodiazepine toxicity but with an accelerated onset. What makes this particularly troubling is that naloxone, the overdose-reversing medication carried by first responders and harm reduction workers, has no effect on benzodiazepines. There is no fast antidote.
Dr. Miriam Levesque, an addiction medicine specialist at the QEII Health Sciences Centre, describes the situation as both predictable and alarming. Benzodiazepines have always carried risk, she explains, but the medical system has protocols in place for managing prescriptions and withdrawal. When those same drugs are synthesized in unregulated labs and sold without dosing information, the margin for error disappears. She has seen patients who thought they were taking a low dose to manage anxiety or insomnia, only to end up in crisis within hours. The drug doesn’t just sedate. It can cause memory blackouts, dangerous interactions with alcohol or opioids, and severe withdrawal symptoms that include hallucinations and life-threatening seizures.
Community outreach workers have been scrambling to get information out. Harm reduction organizations like the South House Sexual and Gender Resource Centre and Mobile Outreach Street Health have been distributing warnings through their networks, emphasizing that this isn’t a drug people can safely experiment with or dose on their own. Even experienced users are at risk. The pills are often sold as “pharmacy grade” or marketed as a safer alternative to street tranquilizers, but lab testing has shown wildly inconsistent concentrations. One pill might contain twice the active ingredient of another from the same batch.
The broader context is hard to ignore. Nova Scotia, like much of Atlantic Canada, has been grappling with an ongoing substance use crisis that has deepened since the pandemic. Economic instability, housing insecurity, and gaps in mental health care have all contributed to rising rates of self-medication and drug use. Benzodiazepines, in particular, have become more sought after as people look for relief from anxiety, trauma, and sleeplessness. But access to prescription supports remains uneven. Wait times for psychiatry or counselling can stretch months. Walk-in clinics are overwhelmed. For some, the street becomes the only option.
Law enforcement is treating the emergence of this synthetic drug as a supply-side issue, but also as a signal of shifting drug markets. Fentanyl and its analogues have dominated headlines for years, but traffickers are increasingly diversifying. Synthetic benzodiazepines are cheaper to produce than pharmaceutical-grade pills and easier to smuggle in bulk. They also fill a demand that opioids alone don’t meet. People want sedation without the high, or they want something to come down from stimulants. The result is a growing number of poly-drug overdoses, where multiple substances interact in ways that are difficult to predict or reverse.
Public health officials are urging anyone who uses drugs, or knows someone who does, to take precautions. That means not using alone, starting with a smaller amount than usual, and avoiding mixing substances. It also means pushing for systemic change. Harm reduction advocates argue that the solution isn’t just better warnings or more enforcement. It’s about expanding access to safe, regulated alternatives and addressing the underlying conditions that drive people toward unregulated drugs in the first place.
Dr. Levesque has been calling for a more integrated approach that includes same-day mental health supports, low-barrier prescribing for people with substance use disorders, and better education around benzodiazepine risks. She points to models in British Columbia and Ontario where supervised consumption sites and drug checking services have helped reduce overdose deaths. Nova Scotia has been slower to adopt these strategies, in part due to political resistance and funding constraints. But the current crisis, she says, makes the case for urgency.
Back in Dartmouth, the pharmacist keeps a list now. Not of names, but of patterns. She watches for repeat requests, unfamiliar prescriptions, and the telltale signs of someone in distress. She has started asking more questions, offering resources, and keeping naloxone kits behind the counter even though she knows they won’t help in every case. It’s not a solution, but it’s something. And in a crisis that moves faster than policy, something is often all anyone has.
